Results 101 to 110 of about 776,387 (309)

Advances in Lymph Node Metastasis and Lymph Node Dissection 
in Early Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2019
Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Non-small cell lung cancer is the main pathological type. Lymph node metastasis is the most common and primary metastatic pathway in non-small cell lung cancer ...
Yun LU, Teng MA, Lei WANG, Tao XUE
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Bidirectional Mendelian randomization identifies differential causal associations between inflammatory cytokines and lung cancer subtypes

Discover Oncology
Highlights Mendelian randomization study on relationships between inflammatory factors and lung cancer risk. Bidirectional two-sample Mendelian randomization approach, utilizing Genome-Wide Association Studies data for two primary lung cancer subtypes ...
Menglu Sun, Xue Gao
doaj   +1 more source

Research Progression of Maintenance Therapy in Small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2015
Lung cancer is one of the common malignant tumors in the world, the incidence of small cell lung cancer is about 15% among them. Small cell lung cancer is highly sensitive to first-line chemotherapy, but most of the patients relapse after the first-line ...
Yunyun LU, Yun FAN
doaj   +1 more source

Technical performance and diagnostic utility of the new Elecsys (R) neuron-specific enolase enzyme immunoassay [PDF]

, 2003
This international multicenter study was designed to evaluate the technical performance of the new double-monoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test ...
Pawel, Joachim von, von Pawel, J., Gurr, E., Stieber, P., Roth, Hans-Jürgen, Fürst, Heinrich, Ebert, W., Raith, Hannelore, Muley, T., Nagel, D., Muley, Thomas, Uhl, Wolfgang, Nagel, Dorothea, Drings, Peter, Holdenrieder, Stefan, Drings, P., Raith, H., Blijenberg, Bert G., Ebert, Werner, Stieber, Petra, Luthe, Hilmar, Uhl, W., Roth, H. J., Blijenberg, B. G., Gurr, Eberhard, Holdenrieder, S.   +25 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC 
(2022 Version)

Chinese Journal of Lung Cancer, 2022
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, Anti-cancer Drug Safety Management Committee (ASMC)   +1 more
doaj   +1 more source

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

MET Inhibition in Non-Small Cell Lung Cancer

European Medical Journal, 2019
Cancer treatment paradigms have evolved over recent years with an emphasis on personalised medicine. Targeted agents are being used to improve treatment outcomes and quality of life.
Shabnam Rehman, Grace K. Dy
doaj